Vanguard (PODD) parent reports 0 shares after realignment; subsidiaries to report
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 14 to Schedule 13G/A reporting that it beneficially owns 0 shares of Insulet Corp Common Stock, representing 0% of the class as disclosed in the amendment.
The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that resulted in certain subsidiaries and business divisions of The Vanguard Group reporting ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports zero beneficial ownership in Insulet after internal realignment.
The amendment states The Vanguard Group's subsidiaries now report holdings separately following an internal realignment referenced to SEC Release No. 34-39538, and the parent reports 0 shares and 0% ownership as of the filing.
Cash-flow treatment or which specific subsidiaries now report holdings is not detailed in the excerpt; subsequent disclosures by the separate reporting entities would show where prior holdings are now recorded.
Amendment documents administrative reallocation of reporting responsibility, not an economic sale.
The filing cites an internal realignment dated 01/12/2026 and explains that certain subsidiaries will report beneficial ownership separately, in reliance on SEC Release No. 34-39538.
This filing itself lists ownership as 0 shares; any investor impact depends on disclosures by the subsidiaries that now hold or report the position.
FAQ
Does The Vanguard Group own Insulet Corp (PODD) shares according to this filing?
What caused The Vanguard Group to report 0 shares in the Schedule 13G/A amendment?
When was the Schedule 13G/A Amendment No. 14 signed for PODD?
Does this Schedule 13G/A indicate a sale of Insulet shares by Vanguard?
Will other Vanguard entities report Insulet holdings after this amendment?